We’re delighted that our founder and CEO, Tiffany Daniels-Thorn, appeared as one of 5 UK founders and innovators to know about on International Women’s Day.
Please find a short section of the article below and you can read the full article at UK Tech News.

‍International Women’s Day is more than just a one-day celebration, it’s about recognising the amazing contributions that women make in all walks of life. This year’s theme is ‘choose to challenge’ bias, inequality and underrepresentation. And nowhere is this more important than across Science, Technology, Engineering and Maths (STEM) – all areas which have historically seen lower numbers of female workers.

Located in a cluster of world-leading life science and tech businesses at Alderley Park is BiVictriX. Founded by Tiffany Thorne, BiVictriX is creating a pipeline of safer and more effective anti-cancer therapies with its unique therapeutic platform, Bi-Cygni. This platform targets BiVictriX’s proprietary library of cancer-specific twin antigen fingerprints that are present on the cancer cells, but are absent from healthy cells in order to reduce the harmful side effects of cancer treatment.

Since its inception in 2017, Tiffany has successfully raised £2.3M investment for BiVictriX with help from Alderley Park’s Accelerator, and continues to develop its game-changing therapies.

Speaking about her journey and the inspiration behind founding BiVictriX, Tiffany said:

“Initially I trained and qualified as a Clinical Immunologist at Manchester Royal Infirmary, where one of my key roles was in the diagnosis and management of some of the most aggressive forms of leukaemia. Here I became aware of the urgent need for safer and more effective therapies to improve patient outcomes and turned my attention to working on next generation antibody based therapeutic approaches.

“I suggested that a concept widely used as an efficient diagnostic platform could be applied, for the first time, to these next generation approaches to form a novel class of therapeutics with superior cancer selectivity. This was the basis for BiVictriX.’’